Results 41 to 50 of about 4,828 (174)

Bridging Genomics and Clinical Medicine: RSVrecon Enhances RSV Surveillance With Automated Genotyping and Clinically Important Mutation Reporting

Influenza and Other Respiratory Viruses, Volume 20, Issue 1, January 2026.
ABSTRACT Background Respiratory Syncytial Virus (RSV) causes significant respiratory infections, particularly in young children and elderly adults. Genetic variations in the fusion (F) protein can reduce the efficacy of vaccination and monoclonal antibody treatments, emphasizing the need for genomic surveillance of this virus.
Lei Li, Haidong Yi, Jessica N. Brazelton, Richard J. Webby, Randall T. Hayden, Gang Wu, Diego R. Hijano   +6 more
wiley   +1 more source

Palivizumab: Four Seasons in Russia

Annals of the Russian academy of medical sciences, 2014
In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically ...
Baranov A.A., Ivanov D.O., Alyamovskaya G.A., Amirova V.R., Antonyuk I.V., Asmolova G.A., Belyaeva I.A., Bokeriya E.L., Bryukhanova O.A., Vinogradova I.V., Vlasova E.V., Galustyan A.N., Gafarova G.V., Gorev V.V., Davydova I.V., Degtyarev D.N., Degtyareva E.A., Dolgikh V.V., Donin I.M., Zakharova N.I., Zernova L.Yu., Zimina E.P., Zuev V.V., Keshishyan E.S., Kovalev I.A., Koltunov I.E., Korsunskii A.A., Krivoshchekov E.V., Krsheminskaya I.V., Kuznetsova S.N., Lyubimenko V.A., Namazova-Baranova L.S., Nesterenko E.V., Nikolaev S.V., Ovsyannikov D.Yu., Pavlova T.I., Potapova M.V., Rychkova L.V., Safarov A.A., Safina A.I., Skachkova M.A., Soldatova I.G., Turti T.V., Filatova N.A., Shakirova R.M., Yanulevich O.S.   +45 more
openaire   +5 more sources

Spatial and temporal variability of respiratory syncytial virus disease seasonality in Japan, 2012–2024

Pediatrics International, Volume 68, Issue 1, January/December 2026.
Abstract Background Understanding infectious disease seasonality is crucial to inform immunization timing and risk communications. This study aimed to describe trends in respiratory syncytial virus (RSV) seasonality in Japan by determining thresholds across 47 prefectures using public health surveillance data. Methods Weekly RSV cases per sentinel (CPS)
Takeshi Arashiro, Ichiro Morioka, Naruhiko Ishiwada, Oliver Martyn, Rolf Kramer, Jing Jin, Amanda Pinho, Ewen Corbelon, Satoshi Kusuda   +8 more
wiley   +1 more source

Therapeutic Antibodies for Mosquito‐Borne Orthoflavivirus Infections: Discovery, Engineering Approaches, and Advances in mRNA‐Based Delivery Systems

Advanced Therapeutics, Volume 8, Issue 12, December 2025.
This review explores how antibody engineering and display technologies are driving therapeutic advances against mosquito‐borne orthoflaviviruses such as Zika, dengue, and yellow fever viruses. It highlights diverse neutralizing targets on the envelope protein, including the conserved fusion loop, and discusses how Fc engineering, rational antigen ...
Ana Clara Barbosa Antonelli, Lucas Silva Rodrigues, Maria Clara Moura Pinheiro, Sylvia Barbosa Pinhate, Marcelo de Macedo Brígido, Andréa Queiroz Maranhão   +5 more
wiley   +1 more source

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation

Health Technology Assessment, 2008
Objectives: To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with ...
D Wang, C Cummins, S Bayliss, J Sandercock, A Burls   +4 more
doaj   +1 more source

Respiratory Syncytial Virus Epidemiology During and After Covid‐19 Pandemic in Africa: Systematic Review and Meta‐Analysis

Health Science Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background and Aims Respiratory syncytial virus (RSV) is a major agent of acute respiratory infections in children and the elderly. RSV epidemiology has been changed by the since Covid‐19 pandemic and this review aimed to assess the extent of this change in Africa.
Moussa Issa, Adamou Lagare, Goni A. M. Bachir, Arnol Bowo ‐Ngandji, Fatimata Hassane, Larwanou Harouna Magagi, Doutchi Mahamadou, Haoua Seini, Eric Adehossi, Alzouma Mayaki Zoubeirou   +9 more
wiley   +1 more source

Management of Infants Treated for Respiratory Viral Infections: A Finnish Retrospective Register‐Based Study

Health Science Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background and Aims Viral respiratory tract infections are common in all age groups, and they are responsible for a vast number of health care visits every year. Furthermore, the incidence of respiratory infections is the highest in children.
Sallamaria Länsisalo, Paula Heikkilä, Sauli Palmu   +2 more
wiley   +1 more source

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro

The Turkish Journal of Pediatrics
Background. Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood.
Envera Lekic, Ljubinka Dragas, Drasko Nikcevic, Jasmina Lekic, Ana Dedic, Ljiljana Sulovic   +5 more
doaj   +1 more source

Respiratory Syncytial Virus (RSV) in an Italian Pediatric Cohort: Genomic Analysis and Circulation Pattern in the Season 2022–2023

Journal of Medical Virology, Volume 97, Issue 11, November 2025.
ABSTRACT There is growing interest in the molecular surveillance of the respiratory syncytial virus (RSV) and data concerning the virus molecular epidemiology in high‐risk pediatric patients in Italy are still limited. A total of 127 RSV‐positive swabs collected in 2022–2023 season were analyzed.
Alessia Lai, Annalisa Bergna, Valentina Fabiano, Carla della Ventura, Hanin Chmes, Alice Romero, Martina Loiodice, Angela Maria Dolores Boria, Alessandro Campagnoli, Felicia Stefania Falvella, Alberto Dolci, Gian Vincenzo Zuccotti, Gianguglielmo Zehender   +12 more
wiley   +1 more source

Real‐World Effectiveness of Nirsevimab in Preventing RSV Hospitalizations: Evidence of Protection in Southern Italian Infants, 2024–2025

Journal of Medical Virology, Volume 97, Issue 11, November 2025.
ABSTRACT Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants, resulting in millions of cases and hundreds of thousands of deaths worldwide every year. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, has 75%–90% protection against RSV‐related admissions.
Francesca Fortunato, Rosa Prato, Angelo Acquafredda, Angelo Campanozzi, Valeria Delli Carri, Rosa Francavilla, Giuseppina Iannelli, Pio Liberatore, Gianfranco Maffei, Matteo Mariano, Loris Micelli, Marilena Nesta, Maria Rosa Pastore, Annamaria Calvo, Matteo Rinaldi, Pier Luigi Lopalco, Domenico Martinelli   +16 more
wiley   +1 more source